Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.

Similarly, the proportion of patients in the favipiravir treatment group who achieved the cessation of oral shedding of the SARS-CoV-2 virus as measured by negative RT-PCR in both oropharyngeal and nasopharyngeal swab at days 4, 7, 10, and 14 was numerically higher at all timepoints when compared with the control group but did not reach statistical significance at any timepoint ( Figure 3 B).

also in 111,027 other papers